Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies

Mycoses

Volumn 54, Issue 5, 2011, Pages 454-459

  Hoenigl, M ^a   Zollner Schwetz, I ^a   Sill, H ^a   Linkesch, W ^a   Lass Florl C ^b   Schnedl, W J ^c   Krause, R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Practice for General Internal Medicine   (Austria)

Author keywords

Antifungal agents; Aspergillosis; Candidiasis; Haematological malignancies; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANCER CHEMOTHERAPY; CANDIDA; CANDIDIASIS; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; SYSTEMIC THERAPY; ZYGOMYCETES;

ADULT; AGED; ANTIFUNGAL AGENTS; CHEMOPREVENTION; FEMALE; FUNGI; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES;

ASPERGILLUS; CANDIDA; FUNGI; ZYGOMYCETES;

EID: 80052821263     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01881.x     Document Type: Article

References (22)

1. Warnock DW. Trends in the epidemiology of invasive fungal infections. Jpn J Med Mycol 2007; 48: 1-12.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
3. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
4. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008; 14(Suppl): 5-24.
5. Hoenigl M, Schwetz I, Wurm R, Scheidl S, Olschewski H, Krause R. Pulmonary histoplasmosis in three Austrian travellers after a journey to Mexico. Infection 2007; 36: 282-4.
6. Bow EJ. Of yeasts and hyphae: a hematologist's approach to antifungal therapy. Hematology (Am Soc Hematol Educ Prog) 2006; 361-7.
7. Cornely OA, Maertens JA, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
8. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
9. Auner HW, Sill H, Muclabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374-7.
10. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) Alliance Registry. Clin Infect Dis 2009; 48: 265-73.
11. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of SEIFEM B-2004 Study. Clin Infect Dis 2007; 45: 1161-70.
12. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
13. Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 2007; 12: 2-6.
14. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal Amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
15. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Hematologica 2006; 91: 1068-75.
16. Auberger J, Lass-Flörl C, Ulmer H et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with haematological malignancies. Int J Hematol 2008; 88: 508-15.
17. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe Graft-versus-Host disease. N Engl J Med 2007; 356: 335-47.
18. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
19. Cornely OA, Böhme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-22.
20. de Pauw BE. Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 2005; 41: 1251-3.
21. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
22. Klastersky J, Paesmans M. Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection. Support Care Cancer 2007; 15: 137-41.